Role of Technetium tetrofosmin scintimammography in the diagnosis of malignant breast masses and axillary lymph node involvement: A comparative study with mammography and histopathology

European Journal of Surgery

Volumn 165, Issue 12, 1999, Pages 1147-1153

  Ortapamuk, Hülya ^a,b   Özmen, M Mahir ^a   Ibis, Sinan ^a   Naldöken, Seniha ^a   Aksoy, Fehmi ^a  

^a ANKARA NUMUNE HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

Breast cancer; Mammography; Radionuclide imaging; Tc 99m tetrofosmin

Indexed keywords

TETROFOSMIN TC 99M;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL; SCINTIMAMMOGRAPHY;

EID: 0033378266     PISSN: 11024151     EISSN: None     Source Type: Journal    
DOI: 10.1080/110241599750007676     Document Type: Article

References (25)

1. Akçay M, Akin Y, Karabag B, Ozcan O, Oren D. Tc-99m tetrofosmin in breast carcinoma and axillary lymph node metastases: a comparative study with Tc-99m MIBI. Clin Nucl Med 1997; 12: 832-834.
2. Campeau RJ, Kronemer KA, Shutherland CM. Concordant uptake of Tc-99m Sestamibi and T1-201 in unsuspected breast tumor. Clin Nuc Med 1992; 17: 936-937.
3. Cistaro A, Bonazzi G, Bello M, et al. Breast carcinoma and axillary lymph node status: the use of 99m Tc-sestamibi scintimammography for the diagnosis and preoperative stating. Preliminary results. Minerva Chir 1997; 52: 1177-1182.
4. Donegan WL. Evaluation of a palpable breast masses. N Engl J Med 1992; 327: 937-942.
5. Fenlon HM, Phelan NC, Osullivan P, Tierney S, Gorey T, Ennis JT. Benign versus malignant breast disease: comparison of contrast-enhaced MR imaging and Tc-99m tetrofosmin scintimammography. Radiology 1997; 205: 214-220.
6. Higley B, Smith T, et al. Technetium-99m-1,2-bis (2-ethoxyethil) phosphine ethane: human biodistribution, dosimetry and safety of a new myocardial imaging agent. J Nucl Med 1993; 34: 30-38.
7. Hisada K, Tonami N, Miyamae T, et al. Clinical evaluation of tumor imaging with T1-201 chloride. Radiology 1978; 129: 497-500.
8. Jackson VP, Hendrick RE, Keig SA, et al. Imaging of the radiographically dense breast. Radiology 1993; 198: 297-301.
9. Kao CH, Wang SJ, Lui TJ. The use of technetium-99m-methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses. Eur J Nucl Med 1994; 21: 432-436.
10. Khalkhali I, Cutrone JA, Mena IG, et al. Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 1995; 196: 421-426.
11. Khalkhali I, Cutrone J, Mena I, et al. Technetium-99m sestamibi scintimammography of breast lesions: clinical and pathologic follow-up. J Nucl Med 1995; 36: 1784-1789.
12. Lind P, Gallowitsch HJ, Kogler D, Kresnik E, Mikosch P, Gomez I. Tc-99m-tetrofosmin scintimammography: a prospective study in primary breast lesions. Nuklearmedizin 1996; 35: 225-229.
13. Madariaga P, Almoguera I, Alonso A, et al. Technetium-99m tetrofosmin scintigraphy to evaluate breast lesions. Anticancer Research 1997; 17: 1619-1622.
14. Mansi L, Rambaldi PF, Procaccini E, et al. Scintimammography with Tc-99m tetrofosmin in the diagnosis of breast cancer and lymph node metastases. J Nucl Med 1996; 23: 932-939.
15. Meyer JE, Eberlein TJ, Stomper PC. Biopsy of occult breast lesions: analysis of 1261 abnormalities. JAMA 1990; 263: 2341-2343.
16. Palmedo H, Schomburg A, Grunwald F, et al. Technetium-99m-MIBI scintimammography for suspicious breast lesions. J Nucl Med 1996; 37: 626-630.
17. Platts EA, North TL, Pickert RD, Kelley JD. Mechanism of uptake of technetium-tetrofosmin: Uptake into isolated adult rat ventricular myocites and subcellular localization. J Nucl Cardiol 1995; 2: 317-326.
18. Rambaldi PF, Mansi L, Procaccini E, Gregorio F, Vecchio E. Breast cancer detection with Tc-99m tetrofosmin. Clin Nucl Med 1995; 20: 703-705.
19. Schillaci O, Scopinaro F, Danielli R, et al. Technetium-99m Sestamibi imaging in the detection of axillary lymph node involvement in patients with breast cancer. Anticancer Research 1997; 17: 1607-1610.
20. Schillaci O, Scopinaro F, Danielli R, et al. Scintimammography with technetium-99m tetrofosmin in suspected breast cancer. Anticancer Research 1997; 17: 1623-1626.
21. Sickels EA. Breast masses: mammographic evaluation. Radiology 1989; 173: 297-303.
22. Taillefer R, Robidoux A, Lambert R, Turpin S, Laperriere J. Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 1995; 36: 1758-1765.
23. Taillefer R, Robidoux A, Turpin S, Lambert R, Cantin J, Leveille J. Metastatic axillary lymph node technetium-99m-MIBI imaging in primary breast cancer. J Nucl Med 1998; 39: 459-464.
24. Uriarte I, Carril JM, Quirce R, et al. Optimization of X-ray mammography and technetium-99m-methoxyisobutlyisonitrile scintimammography in the diagnosis of non-palpable breast lesions. Eur J Nucl Med 1998; 25: 491-496.
25. Vieria MR, Weinholtz JH. Tc-99m tetrofosmin scintigraphy in the diagnosis of breast cancer. Eur J Surg Oncol 1996; 22: 331-334.